England’s NICE Backs Ultragenx’s Rare Disease Drug Evkeeza After Applying Anti-Discrimination Principles
Executive Summary
NICE, the health technology assessment body for England and Wales, looked beyond cost-effectiveness measures alone in its appraisal of Ultragenx’s rare disease drug Evkeeza, resulting in a positive reimbursement recommendation for all eligible patients.